Molecule News and Research

RSS

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

REST molecule acts as an adapter in stem cells, times neuronal development

Upon fertilisation, a single cell is formed when egg and sperm fuse. Our entire body, with more than 200 specialised cell types and billions of cells are formed from this single cell. It is a scientific mystery how the early stem cells know what cell type to become, but a precise timing of the process is crucial for correct development and function of our body.

3 Mar 2012

Critical new details about structure of enterovirus 71

Researchers have discovered critical new details about the structure of a virus that causes potentially fatal brain swelling and paralysis in children, pointing toward designs for antiviral drugs to treat the disease.

3 Mar 2012

Scientists determine chemical features of DHPS enzyme's active site

More than 70 years after the first sulfa drugs helped to revolutionize medical care and save millions of lives, St. Jude Children's Research Hospital scientists have determined at an atomic level the mechanism these medications use to kill bacteria. The discovery provides the basis for a new generation of antibiotics that would likely be harder for bacteria to resist and cause fewer side effects.

2 Mar 2012

Combining two common cancer-fighting strategies may have 'tremendous synergy'

Researchers at the University of Illinois at Chicago College of Medicine have found that a molecule found at elevated levels in cancer cells seems to protect them from the "cell-suicide" that is usually triggered by chemotherapy or radiation.

2 Mar 2012

Conference on follow-on versions of complex drugs

On March 9, the New York Academy of Sciences will present "Scientific Considerations for Complex Drugs in Light of Established Regulatory Guidance." This full-day conference will explore current definitions, global scientific and regulatory hurdles, and future challenges for follow-on versions of complex drugs.

2 Mar 2012

New HS44 molecule inhibits lung metastasis

One type of white blood cell, the Natural Killer T Cells, fights against infections and tumours by freeing cytokine proteins which activate the body's immune response and destroy infected or malignant cells. To do so they must receive an activation signal. Specific receptors located on their surface act as switches: they activate the lymphocyte in presence of an antigen, a molecule which triggers alarm signals.

2 Mar 2012

New method for creating nanofibers could improve drug delivery methods

A new method for creating nanofibers made of proteins, developed by researchers at Polytechnic Institute of New York University (NYU-Poly), promises to greatly improve drug delivery methods for the treatment of cancers, heart disorders and Alzheimer's disease, as well as aid in the regeneration of human tissue, bone and cartilage.

1 Mar 2012

HDAC2 enzyme could be a potential target for new Alzheimer's drugs

MIT neuroscientists have shown that an enzyme overproduced in the brains of Alzheimer's patients creates a blockade that shuts off genes necessary to form new memories. Furthermore, by inhibiting that enzyme in mice, the researchers were able to reverse Alzheimer's symptoms.

1 Mar 2012

LAU-0901 drug protects brain in an experimental stroke model

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke.

29 Feb 2012

Tiny molecule might help protect pancreas from cancer

A tiny molecule might help protect the pancreas from deadly disease and cancer. Tackling a mysterious process: There is a feeling that neglected cancers need more research and Pancreatic cancer is one of the least studied. Today, the survival rate is 3% for five years. Professor Petersen, at the School of Biosciences at Cardiff University, hopes his team's research can change that.

29 Feb 2012

CNRS/Inserm researchers discover new family of anti-cancer compounds

A French-Italian team headed by researchers from CNRS and Inserm has discovered a new family of compounds that could make it possible to treat numerous cancers, particularly brain tumors and skin cancers.

28 Feb 2012

EMBL-EBI launches Enzyme Portal

The European Molecular Biology Laboratory's European Bioinformatics Institute has launched the Enzyme Portal, a freely available resource for people who are interested in the biology of enzymes and proteins with enzymatic activity.

28 Feb 2012

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide.

27 Feb 2012

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

A Saint Louis University investigator noted for her pain research is working to reduce a painful chemotherapy side effect, thanks to a $126,500 grant from the Mayday Fund, an organization dedicated to alleviating the incidence, degree and consequence of human physical pain.

27 Feb 2012

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Bath salts mimic effects of two powerful narcotics

The street drug commonly referred to as "bath salts" is one of a growing list of synthetic and unevenly regulated narcotics that are found across the United States and on the Internet. New research on this potent drug paints an alarming picture, revealing that bath salts pack a powerful double punch, producing combined effects similar to both methamphetamine (METH) and cocaine.

24 Feb 2012

Unfolded end of Colicin N protein can kill antibiotic-resistant microbes

When bacteria wage a turf war, some of the combatants have an extra weapon. Certain strains of the bacteria E. coli produce proteins that kill competing E. coli and other like microbes, and researchers from Newcastle University in England have recently discovered something surprising about one of these lethal proteins: even after the toxic folded portion of the protein is removed, the unfolded end is still deadly.

24 Feb 2012

Scientists identify specific mechanisms by which vitamin D inhibits inflammation

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling.

24 Feb 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012